PT  - JOURNAL ARTICLE
AU  - Daulagala, Pavithra
AU  - Cheng, Samuel M. S.
AU  - Chin, Alex W. H.
AU  - Luk, Leo L. H.
AU  - Leung, Kathy
AU  - Wu, Joseph T.
AU  - Poon, Leo L. M.
AU  - Peiris, Malik
AU  - Yen, Hui-Ling
TI  - Healthy adults possess cross-reactive neuraminidase inhibition antibodies to an A(H5N1) clade 2.3.4.4b avian influenza virus A/Black Faced Spoonbill/Hong Kong/AFCD-HKU-22-21429-01012/2022
AID  - 10.1101/2023.06.23.23291839
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.23.23291839
4099  - http://medrxiv.org/content/early/2023/06/27/2023.06.23.23291839.short
4100  - http://medrxiv.org/content/early/2023/06/27/2023.06.23.23291839.full
AB  - Hemagglutination inhibition (HI) and neuraminidase inhibition (NI) antibodies to a clade 2.3.4.4b A(H5N1) highly pathogenic avian influenza virus were measured in 63 age-stratified healthy adults in Hong Kong. No HI antibody was detected; 61 subjects had detectable NI antibodies to A(H5N1). NI titers to A(H5N1) and A(H1N1)pdm09 viruses were correlated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by RGC Theme-based Research Schemes (T11-712/19-N), Hong Kong SAR, China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of Hong Kong/Hospital Authority Hong Kong West Cluster gave human ethics approval for this work (#UW-132)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors